Cited 10 times in
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍민희 | - |
dc.date.accessioned | 2023-03-21T07:33:47Z | - |
dc.date.available | 2023-03-21T07:33:47Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.issn | 2218-6751 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193438 | - |
dc.description.abstract | Background: Irrespective of the first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor chosen, acquired resistance to therapy is inevitable. Therefore, a key consideration when assessing therapeutic choices is the availability of subsequent treatment options following disease progression. We assessed clinical outcomes in patients who received first-line afatinib treatment with various second-line treatments including osimertinib for patients acquiring the T790M mutation. Methods: A total of 737 EGFR mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients receiving first-line afatinib treatment were categorized by second-line treatment: T790M+ sequentially treated with osimertinib (cohort A, n=116); T790M- given chemotherapy or others (cohort B, n=143); patients with unknown T790M status (cohort C, n=111); and patients who were undergoing afatinib treatment at the time of data collection, were dead, had discontinued afatinib treatment due to serious adverse events or were lost to follow-up (cohort D, n=367). The primary outcomes were total time on treatment (TOT) and TOT for first-line (TOT-1) and second-line treatments (TOT-2). Secondary outcomes were objective response rates (ORR), overall survival (OS), and central nervous system (CNS) efficacy. Results: Median total TOT in cohorts A, B, C, and D were 35.10 months [95% confidence interval (CI): 30.09-43.53 months], 18.80 months (95% CI: 16.92-20.20 months), 12.00 months (95% CI: 10.22-14.98 months), and 42.60 months (95% CI: 30.95-59.23 months), respectively. The ORR of patients given afatinib was 75.7%. In patients with initial brain metastasis without local treatment, the CNS response rate was 67.0% and CNS progression-free survival was 24.70 months (95% CI: 19.84-33.15 months). Conclusions: This study showed that sequential approach of afatinib followed by second line treatment is an effective therapeutic strategy for EGFR M+ NSCLC patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Pioneer Bioscience Publishing Company | - |
dc.relation.isPartOf | TRANSLATIONAL LUNG CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyun Ae Jung | - |
dc.contributor.googleauthor | Min Hee Hong | - |
dc.contributor.googleauthor | Hyun Woo Lee | - |
dc.contributor.googleauthor | Kyung Hee Lee | - |
dc.contributor.googleauthor | Il Hwan Kim | - |
dc.contributor.googleauthor | Young Joo Min | - |
dc.contributor.googleauthor | Hee Kyung Ahn | - |
dc.contributor.googleauthor | Byoung Yong Shim | - |
dc.contributor.googleauthor | Yoon Hee Choi | - |
dc.contributor.googleauthor | Yun-Gyoo Lee | - |
dc.contributor.googleauthor | Jeong A Kim | - |
dc.contributor.googleauthor | Joung Soon Jang | - |
dc.contributor.googleauthor | Seong-Hoon Shin | - |
dc.contributor.googleauthor | Keon Uk Park | - |
dc.contributor.googleauthor | Jin Hyoung Kang | - |
dc.contributor.googleauthor | Keunchil Park | - |
dc.identifier.doi | 10.21037/tlcr-22-79 | - |
dc.contributor.localId | A04393 | - |
dc.relation.journalcode | J03382 | - |
dc.identifier.eissn | 2226-4477 | - |
dc.identifier.pmid | 35958320 | - |
dc.subject.keyword | Non-small cell lung cancer (NSCLC) | - |
dc.subject.keyword | afatinib | - |
dc.subject.keyword | epidermal growth factor receptor (EGFR) | - |
dc.subject.keyword | sequential treatment | - |
dc.subject.keyword | tyrosine kinase inhibitor (TKI) | - |
dc.contributor.alternativeName | Hong, Min Hee | - |
dc.contributor.affiliatedAuthor | 홍민희 | - |
dc.citation.volume | 11 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1369 | - |
dc.citation.endPage | 1379 | - |
dc.identifier.bibliographicCitation | TRANSLATIONAL LUNG CANCER RESEARCH, Vol.11(7) : 1369-1379, 2022-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.